Berobenatide monthly injections for sleep apnea in adults with overweight or obesity
Tests berobenatide against placebo in adults with sleep apnea and overweight or obesity.
Key facts
- Who runs it
- Pfizer
- Where
- Bradenton, Cullman, Maplewood, and Tomball, United StatesSee the 4 sites
- Trial code
- Registry title
- A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 258 people, planned
- Started
- 19 Oct 2026
- Expected to end
- 20 Jul 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Berobenatide
- Placebo
- Record updated
- 6 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderate to severe obstructive sleep apnea who are overweight or have obesity and do not use a breathing machine (PAP). It tests monthly injections of berobenatide against placebo.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Previously diagnosed moderate to severe obstructive sleep apnea (OSA), with a body mass index (BMI) of 27 kg/m² or more at screening.
- Earlier treatment
- Unable or unwilling to use positive airway pressure (PAP) therapy, with no PAP use for at least 4 weeks before screening.
Main reasons for not taking part
- Body weight change of more than 5% within 90 days before screening (self-reported)
- Any type of diabetes (resolved gestational diabetes is allowed)
- History of acute or chronic pancreatitis
- Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2)
- Other sleep breathing problems that could affect the study results, such as central sleep apnea or obesity hypoventilation syndrome
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Adults aged 18 years or older
- Body mass index (BMI) ≥27 kg/m² at screening
- Previously diagnosed with moderate to severe obstructive sleep apnea (OSA)
- Unable or unwilling to use positive airway pressure (PAP) therapy, and no use of PAP therapy for at least 4 weeks prior to screening
Who cannot take part
- Self-reported body weight change of more than 5% within 90 days prior to screening
- Diagnosis of any type of diabetes (resolved gestational diabetes is permitted)
- History of acute or chronic pancreatitis
- Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2) Sleep-disordered breathing conditions other than obstructive sleep apnea that could interfere with study assessments or interpretation of results (eg, central sleep apnea, mixed sleep apnea, Cheyne-Stokes respiration, obesity hypoventilation syndrome, or significant craniofacial abnormalities)
Where in United States
- DM Clinical Research-BradentonBradenton, United StatesTaking people
- Cullman Clinical TrialsCullman, United StatesTaking people
- Headlands Research-Twin CitiesMaplewood, United StatesTaking people
- DM Clinical Research, TomballTomball, United StatesNot yet recruiting
About the trial
What the trial wants to find out
This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if berobenatide can help adults with breathing problems during sleep (obstructive sleep apnea [OSA]) and overweight or obesity who are not using a breathing machine (positive airway pressure [PAP] machine).
Read full original descriptionShow less
People may be able to take part if they are adults with moderate to severe OSA, have overweight or obesity, and have been unable or unwilling using PAP therapy before joining the study. Participants will be assigned by chance to receive either berobenatide or a placebo (a treatment that looks like the study medicine but contains no active medicine). The study treatment will be given as an injection under the skin approximately once a month. Participants will receive study treatment at study sites and may administer some doses at home after receiving training.
During the study, participants will attend study visits, undergo sleep studies, complete questionnaires, and have health assessments performed. Researchers will compare the effects of berobenatide and placebo on sleep apnea, body weight, and other health measures.
The 2 groups in the trial
- BerobenatideTreatment being tested
Participants receive berobenatide by subcutaneous injection.
- PlaceboPlacebo, for comparison
Participants receive volume-matched placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH OBSTRUCTIVE SLEEP APNEA AND OVERWEIGHT OR OBESITY NOT RECEIVING POSITIVE AIRWAY PRESSURE THERAPY (VESPER-OSA 2)
- Plain-language title
- Berobenatide monthly injections for sleep apnea in adults with overweight or obesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 6 November 2026